A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Mikhael, J; Belhadj-Merzoug, K; Hulin, C; Vincent, L; Moreau, P; Gasparetto, C; Pour, L; Spicka, I; Vij, R; Zonder, J; Atanackovic, D; Gabrail, N; Martin, TG; Perrot, A; Bensfia, S; Weng, Q; Brillac, C; Semiond, D; Macé, S; Corzo, KP; Leleu, X

Published Date

  • May 12, 2021

Published In

Volume / Issue

  • 11 / 5

Start / End Page

  • 89 -

PubMed ID

  • 33980831

Pubmed Central ID

  • PMC8116334

Electronic International Standard Serial Number (EISSN)

  • 2044-5385

Digital Object Identifier (DOI)

  • 10.1038/s41408-021-00478-4


  • eng

Conference Location

  • United States